We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Pharmacovigilance Panel Makes Moves on Cancer, MS Drugs
EMA Pharmacovigilance Panel Makes Moves on Cancer, MS Drugs
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee declared the chemotherapy drug docetaxel safe to use after it concluded that there is no evidence of changes in the known risk of intestinal inflammation after treatment.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor